Vital Transformation understands the implications of new medical procedures, technologies and policies. We measure their impact on current clinical practices in close collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders. Vital Transformation has presented or participated in conferences sponsored by The Royal College of Physicians, European Health Forum Gastein, The European Commission, London Genetics, The European Science Foundation, The European Microelectronics Summit, and others. Our Vital Transformation branded round-tables, webinars, and conferences are often oversubscribed, and are regularly presented in partnership with global thought-leaders and organisations.
OUR RESEARCH
VT Research Finds a 37% Decline in Small-Molecule Oncology Follow-On Research Following the Inflation Reduction Act
Key Findings
1. Decline in overall follow-on research
The observed number of follow-on studies decreased by approximately 12%, from 610 before the IRA to 535 afterward. Oncology accounted for much of this decline, with the observed number of follow-on cancer studies falling by 20%, from 325 to 260.
2. Significant decline in small-molecule cancer research
The study’s statistical models estimated a 37% decline in the average annual number of small-molecule oncology follow-on studies, from 52 before the IRA to 33 afterward. The analysis also identified a modeled 27% decline in lead-indication small-molecule oncology approvals.
These findings provide evidence that research involving small-molecule cancer medicines may have been particularly affected following the IRA’s introduction.
3. Reduced share of research targeting rare cancers
The proportion of follow-on oncology studies focused on rare diseases, known as orphan indications, declined by 14% after the IRA’s introduction. This finding raises questions about the potential implications for research involving patients with rare cancers and limited treatment options.
4. Different trends in hematology
In contrast to oncology, the study found an increase in follow-on small-molecule hematology studies. However, this increase started from a low baseline, and the overall findings for hematology differed from those for oncology.
Antimicrobial Resistance (AMR) Project
- Antimicrobial resistance (AMR) increases healthcare costs, hospital stays, and readmission rates, creating a growing economic burden on the U.S. healthcare system.
- Based on a cohort of 50,189 patients, with 13% experiencing AMR infections, the following impacts were observed:
- An additional 4 days of hospitalization per AMR infection.
- An additional $21,453 in direct medical costs per AMR infection.
- A 28% hospital readmission rate for AMR patients, compared to 21% for non-AMR patients.
- AMR is estimated to cost the U.S. $31 billion annually in 2025, increasing to $52 billion by 2045.
- The projected 20-year economic burden of AMR in the U.S. is $655 billion in net present value.
PREPRINT NEW RESEARCH: The Inflation Reduction Act’s Impact Upon Late-Stage R&D
Vital Transformation is preparing a new analysis with a total of 1148 secondary trials from 364 FDA-approved medicines, published from 2018 to 2025, obtained from Biomedtracker and clinicaltrials.gov. Using fractional multinomial logit, we model the share distribution of secondary indication studies across 19 disease groups and assess the change in this distribution post-IRA. We also assessed the number of secondary treatment studies pre- vs. post-IRA using multiple linear regression.
PODCASTS
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…
Our clients include many of the world’s leading health care organisations.
